Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study

Fig. 2

a Percentage of patients who reported a headache-related hospitalization in the 3 months prior to baseline or since the last onabotulinumtoxinA administration for follow-up visits; b Percentage of patients who visited any HCP in the 3 months prior to baseline or since the last onabotulinumtoxinA administration for follow-up visits. The number of patients in administration (Admin) visits for the overall and German populations are as follows: Admin 1, n = 633 overall, n = 377 Germany; Admin 3, n = 485 overall, n = 270 Germany; Admin 5, n = 371 overall, n = 210 Germany; Admin 8, n = 200 overall, n = 123 Germany. *P < 0.02, **P < 0.0001 McNemar test for difference versus baseline (level of significance, 5%). Abbreviations: Admin, administration; HCP, healthcare professional

Back to article page